Literature DB >> 25665814

Glycemic Control in Simultaneous Islet-Kidney Versus Pancreas-Kidney Transplantation in Type 1 Diabetes: A Prospective 13-Year Follow-up.

Roger Lehmann1, Jessica Graziano1, Jens Brockmann2, Thomas Pfammatter3, Philipp Kron2, Olivier de Rougemont2, Thomas Mueller4, Richard A Zuellig1, Giatgen A Spinas1, Philipp A Gerber5.   

Abstract

OBJECTIVE: In patients with type 1 diabetes and end-stage renal disease, combined transplantation of a kidney together with a pancreas or isolated pancreatic islets are options to improve glycemic control. The aim of this study was to compare their long-term outcome with regard to metabolic control and surgical complication rate, as well as function of the transplanted kidney. RESEARCH DESIGN AND METHODS: We conducted a prospective cohort study in consecutive patients receiving either a pancreas or islet transplant simultaneously with or after kidney transplantation (simultaneous pancreas-kidney [SPK]/pancreas-after-kidney [PAK] or simultaneous islet-kidney [SIK]/islet-after-kidney [IAK] transplantation).
RESULTS: Ninety-four patients who had undergone SPK/PAK transplantation were compared with 38 patients who had undergone SIK/IAK transplantation over a period of up to 13 years. HbA1c levels declined from 7.8 ± 1.3% (62 ± 14 mmol/mol) to 5.9 ± 1.1% (41 ± 12 mmol/mol), and from 8.0 ± 1.3% (64 ± 14 mmol/mol) to 6.5 ± 1.1% (48 ± 12 mmol/mol), respectively, in the SPK/PAK and SIK/IAK groups (P < 0.001 for both) and remained stable during follow-up, despite a reduction in the rate of severe hypoglycemia by >90%. The 5-year insulin independence rate was higher in the SPK/PAK group (73.6 vs. 9.3% in the SIK/IAK group), as was the rate of relaparotomy after transplantation (41.5 vs. 10.5% in the SIK/IAK group). There was no difference in the rate of kidney function decline.
CONCLUSIONS: During a long-term follow-up, SPK/PAK transplantation as well as SIK/IAK transplantation resulted in a sustained improvement of glycemic control with a slightly higher glycated hemoglobin level in the SIK/IAK group. While insulin independence is more common in whole-organ pancreas recipients, islet transplantation can be conducted with a much lower surgical complication rate and no difference in kidney function decline.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25665814     DOI: 10.2337/dc14-1686

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  17 in total

1.  Benefits of Islet Transplantation as an Alternative to Pancreas Transplantation: Retrospective Study of More Than 10 Ten Years of Experience in a Single Center.

Authors:  Barbora Voglová; Martina Zahradnická; Peter Girman; Jan Kríž; Zuzana Berková; Tomáš Koblas; Ema Vávrová; Lenka Németová; Lucie Kosinová; David Habart; Eva Fábryová; Eva Dovolilová; Ivan Leontovyc; Tomáš Neškudla; Jan Peregrin; Jozef Kovác; Kvetoslav Lipár; Matej Kocík; Tomáš Marada; Jirí Svoboda; František Saudek
Journal:  Rev Diabet Stud       Date:  2017-06-12

Review 2.  Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.

Authors:  Pratik Choudhary; Michael R Rickels; Peter A Senior; Marie-Christine Vantyghem; Paola Maffi; Thomas W Kay; Bart Keymeulen; Nobuya Inagaki; Frantisek Saudek; Roger Lehmann; Bernhard J Hering
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

Review 3.  Advances in β-cell replacement therapy for the treatment of type 1 diabetes.

Authors:  Marie-Christine Vantyghem; Eelco J P de Koning; François Pattou; Michael R Rickels
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

4.  Engineering Strategies to Improve Islet Transplantation for Type 1 Diabetes Therapy.

Authors:  Alisa M White; James G Shamul; Jiangsheng Xu; Samantha Stewart; Jonathan S Bromberg; Xiaoming He
Journal:  ACS Biomater Sci Eng       Date:  2019-12-02

5.  Islet cell transplant: Update on current clinical trials.

Authors:  Christian Schuetz; James F Markmann
Journal:  Curr Transplant Rep       Date:  2016-05-17

6.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters
Journal:  Diabetologia       Date:  2021-12       Impact factor: 10.122

7.  Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes.

Authors:  Michael R Rickels; Amy J Peleckis; Eileen Markmann; Cornelia Dalton-Bakes; Stephanie M Kong; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

8.  A Comparative Analysis of the Safety, Efficacy, and Cost of Islet Versus Pancreas Transplantation in Nonuremic Patients With Type 1 Diabetes.

Authors:  S Moassesfar; U Masharani; L A Frassetto; G L Szot; M Tavakol; P G Stock; A M Posselt
Journal:  Am J Transplant       Date:  2015-11-23       Impact factor: 8.086

Review 9.  Progress in understanding type 1 diabetes through its genetic overlap with other autoimmune diseases.

Authors:  Jeffrey D Roizen; Jonathan P Bradfield; Hakon Hakonarson
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 10.  The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus.

Authors:  Philipp A Gerber; Guy A Rutter
Journal:  Antioxid Redox Signal       Date:  2016-06-30       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.